je.st
news
Tag: combination
New Data for KEYTRUDA (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting
2016-06-05 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from three separate studies evaluating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in combination with other treatment regimens including talimogene laherparepvec, dabrafenib plus trametinib, or low-dose ipilimumab in patients with advanced melanoma. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orInvestor Contacts:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
presented
meeting
New Data Evaluating KEYTRUDA (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging from 48 to 71 Percent
2016-06-04 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Based on Initial Results Presented at 2016 ASCO Annual Meeting, Merck Has Initiated Two Phase 3 Studies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from an initial proof-of-concept study of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, combined with standard treatments, one with bevacizumab and others without, in non-small cell lung cancer (NSCLC) including chemotherapy in previously untreated patients with NSCLC; the study showed overall response rates (ORR) ranging from 48 to 71 percent, depending on the therapy used. Language: English Contact: MerckMedia Contacts:Pamela Eisele, (267) 305-3558orCourtney Ronaldo, (908) 236-1108orInvestor Contacts:Teri Loxam, (908) 740-1986orJustin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
HP takes first step toward digital combination printing
2016-06-01 18:02:00| Label and Narrow Web Breaking News
HP is showing at drupa how SmartStream Mosaic-powered technology can print tactile varnishes, cold foil, embossing and more.
Tags: digital
step
takes
combination
Cerulean Announces First Patient Dosed In Phase 1/2 Trial Evaluating CRLX101 In Combination With LYNPARZA
2016-06-01 06:09:24| drugdiscoveryonline Home Page
Cerulean Pharma Inc., a clinical-stage company developing nanoparticle-drug conjugates (NDCs), recently announced that the first patient has been dosed in an open-label, single center Phase 1/2 clinical trial of its lead NDC candidate, CRLX101, in combination with LYNPARZA (olaparib) in patients with advanced solid tumors
Tags: with
trial
combination
phase
DeZURIK Introduces New High Pressure Combination Air Valve
2016-05-25 04:38:31| oilandgasonline Home Page
DeZURIK/APCO/Hilton is introducing a new high pressure combination air valve, the ASU-CAV.
Tags: high
air
combination
pressure
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] next »